Roger N, Popovic I, Madelenat P, Mahieu-Caputo D
Service de Gynécologie-Obstétrique, Maternité Aline-de-Crépy, Hôpital Bichat-Claude-Bernard, APHP, Université Paris-VII, 75018 Paris, France.
Gynecol Obstet Fertil. 2007 Jun;35(6):556-60. doi: 10.1016/j.gyobfe.2007.03.015. Epub 2007 Jun 1.
The fetal toxicity of angiotensin-converting enzyme inhibitors (ACEI) is now well known. Sartans which are angiotensin II inhibitors, are supposed to have the same side effects on the fetus as ACEI because of their similar mechanism of action. This is supported by experimental and clinical data. Clinical presentation of fetal exposition to sartans varies from transient oligamnios to permanent renal failure, potentially complicated by Potter syndrome. According to previously reported cases, we report a case of transitory fetal oliguria secondary to the exposure to an angiotensin-II-receptor inhibitor (valsartan) between 19 and 21 weeks' gestation. We discuss the management of pregnancies exposed to angiotensin II inhibitors.
血管紧张素转换酶抑制剂（ACEI）的胎儿毒性现已广为人知。作为血管紧张素II抑制剂的沙坦类药物，因其作用机制相似，被认为对胎儿有与ACEI相同的副作用。这得到了实验和临床数据的支持。胎儿接触沙坦类药物的临床表现从短暂羊水过少到永久性肾衰竭不等，可能并发波特综合征。根据先前报道的病例，我们报告一例妊娠19至21周期间因接触血管紧张素II受体抑制剂（缬沙坦）继发短暂性胎儿少尿的病例。我们讨论了接触血管紧张素II抑制剂的妊娠的管理。
